Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Autor: Schultheis, B. ^*, Reuter, D., Ebert, M.P., Siveke, J., Kerkhoff, A., Berdel, W.E., Hofheinz, R., Behringer, D.M., Schmidt, W.E., Goker, E., De Dosso, S., Kneba, M., Yalcin, S., Overkamp, F., Schlegel, F., Dommach, M., Rohrberg, R., Steinmetz, T., Bulitta, M., Strumberg, D.

Publikováno v: In Annals of Oncology October 2017 28(10):2429-2435

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

Autor: Tatli A.M., Yumuk P.F., Oz B., Bilici A., Gursoy P., Goker E., Sezer A.

Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. We aimed to study the impact o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______9436::2ce0b19e5f6e529db713178eb70780e6
https://hdl.handle.net/11454/80121

Fasting mimicking diet as an adjunct toneoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Autor: Groot, S. de, Lugtenberg, R.T., Cohen, D., Welters, M.J.P., Ehsan, I., Vreeswijk, M.P.G., Smit, V.T.H.B.M., Graaf, H. de, Heijns, J.B., Portielje, J.E.A., Wouw, A.J. van de, Imholz, A.L.T., Kessels, L.W., Vrijaldenhoven, S., Baars, A., Kranenbarg, E.M.K., Duijm-de Carpentier, M., Putter, H., Hoeven, J.J.M. van der, Nortier, J.W.R., Longo, V.D., Pijl, H., Kroep, J.R., Goker, E., Pas, A.J.M., Honkoop, A.H., Dutch Breast Canc Res Grp BOOG

Publikováno v: Nature Communications, 11
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications, 11(1). NATURE PUBLISHING GROUP
Nature Communications, 11, 1
Nature Communications

Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m−2, to r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906599da7dc475c6bbe7b08453119143
https://hdl.handle.net/1887/3181368

Pancreatic Resections for Oligometastatic Pancreatic Carcinoma

Autor: Avci, G., Unalp, O., Pehlivan, F., Ortac, R., Bulut, G., Arslan, K., Goker, E., Çoker, A.

Publikováno v: In HPB 2023 25 Supplement 2:S498-S498